ReviewInternational journal of environmental research and public health2012
DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.
Review in International journal of environmental research and public health, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Association of the hOGG1 Ser326Cys polymorphism with gynecologic cancer susceptibility: a meta-analysis.Bioscience reports · 2020Pooled it
- The association of six non-synonymous variants in three DNA repair genes with hepatocellular carcinoma risk: a meta-analysis.Journal of cellular and molecular medicine · 2016Pooled it
- Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.Mutation research. Reviews in mutation researchPooled it
- Perspectives on cancer therapy-synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges.Cell death discovery · 2025Review
- Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin.Frontiers in oncology · 2022Article
- Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.Cancer science · 2021Article
- The Oxidative Stress Parameters as Useful Tools in Evaluating the DNA Damage and Changes in the Complete Blood Count in Hospital Workers Exposed to Low Doses of Antineoplastic Drugs and Ionizing Radiation.International journal of environmental research and public health · 2021Article
- Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review.Oncology and therapy · 2020Review
- TNF-α G-308A genetic variants, serum CRP-hs concentration and DNA damage in obese women.Molecular biology reports · 2020Article
- Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells.Frontiers in oncology · 2020Article
- Poly(ADP-ribose) polymerase-3 overexpression is associated with poor prognosis in patients with breast cancer following chemotherapy.Oncology letters · 2018Article
- Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.The oncologist · 2016Review
- Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy.Oncotarget · 2016Review
- Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: a case report.World journal of gastroenterology · 2015Article
- microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.Biomarkers in medicine · 2015Review
- Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells.PloS one · 2015Article
- Article
- Autophagy and genomic integrity.Cell death and differentiation · 2013Review
- Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who?Oncoimmunology · 2013Article
- Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most antitumour therapies damage tumour cell DNA either directly or indirectly. Without repair, damage can result in genetic instability and eventually cancer. The strong association between the lack of DNA damage repair, mutations and cancer is dramatically demonstrated by a number of cancer-prone human syndromes, such as xeroderma pigmentosum, ataxia-telangiectasia and Fanconi anemia. Notably, DNA damage responses, and particularly DNA repair, influence the outcome of therapy. Because DNA repair normally excises lethal DNA lesions, it is intuitive that efficient repair will contribute to intrinsic drug resistance. Unexpectedly, a paradoxical relationship between DNA mismatch repair and drug sensitivity has been revealed by model studies in cell lines. This suggests that connections between DNA repair mechanism efficiency and tumour therapy might be more complex. Here, we review the evidence for the contribution of carcinogenic properties of several drugs as well as of alterations in specific mechanisms involved in drug-induced DNA damage response and repair in the pathogenesis of therapy-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.